Wall Street analysts expect Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) to post $0.35 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Elanco Animal Health’s earnings, with estimates ranging from $0.34 to $0.37. Elanco Animal Health reported earnings per share of $0.37 in the same quarter last year, which indicates a negative year over year growth rate of 5.4%. The company is scheduled to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Elanco Animal Health will report full year earnings of $1.21 per share for the current year, with EPS estimates ranging from $1.19 to $1.23. For the next financial year, analysts forecast that the company will post earnings of $1.49 per share, with EPS estimates ranging from $1.42 to $1.52. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Elanco Animal Health.
Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly earnings data on Wednesday, February 23rd. The company reported $0.21 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.04. Elanco Animal Health had a negative net margin of 9.91% and a positive return on equity of 6.59%. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter last year, the company earned $0.12 EPS. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year.
Shares of NYSE ELAN opened at $25.83 on Friday. Elanco Animal Health has a one year low of $24.15 and a one year high of $37.49. The business’s 50-day moving average price is $26.44 and its two-hundred day moving average price is $28.81. The company has a market capitalization of $12.22 billion, a P/E ratio of -26.91, a price-to-earnings-growth ratio of 1.11 and a beta of 0.78. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.99 and a quick ratio of 1.16.
In related news, Director R David Hoover bought 5,000 shares of Elanco Animal Health stock in a transaction dated Tuesday, March 1st. The shares were bought at an average cost of $28.66 per share, with a total value of $143,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 6.11% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Clearstead Advisors LLC bought a new position in Elanco Animal Health during the third quarter worth $31,000. Herold Advisors Inc. bought a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $31,000. CKW Financial Group bought a new position in Elanco Animal Health during the fourth quarter worth $30,000. First Horizon Advisors Inc. acquired a new stake in Elanco Animal Health in the third quarter worth $36,000. Finally, Benjamin Edwards Inc. increased its stake in Elanco Animal Health by 157.1% in the fourth quarter. Benjamin Edwards Inc. now owns 1,427 shares of the company’s stock valued at $40,000 after purchasing an additional 872 shares in the last quarter. Hedge funds and other institutional investors own 97.90% of the company’s stock.
Elanco Animal Health Company Profile (Get Rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
- Get a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.